F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 22, 2018 | Debt Financing | €24M | 1 | European Investment Bank | — | Detail |
Sep 5, 2012 | Series Unknown | $30M | 1 | — | — | Detail |
Aug 18, 2008 | Series Unknown | £6.30M | 2 | BankInvest Biomedical Venture | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 17, 2022
Heroic Story
|
Seed | $6M | Cryptocurrency | — |
Apr 1, 2014
Flexport
|
Series A | $6.90M | Freight Service | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Debt Financing |
BankInvest Biomedical Venture | Yes | Series Unknown |
K Nominees | — | Series Unknown |